Loading...
•
Jun 30, 2021
Gossamer Bio Q2 2021 Earnings Report
Announced second quarter 2021 financial results and provided a corporate update.
Key Takeaways
Gossamer Bio reported cash, cash equivalents and marketable securities totaling $406 million as of June 30, 2021. The company's net loss for the quarter ended June 30, 2021, was $59.8 million, or $0.80 per share.
Seralutinib and GB004 continue to enroll ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively
Gossamer announced Seralutinib Open Label Extension Data in PAH Patients
Gossamer to discontinue clinical development of GB1275
Cash, cash equivalents and marketable securities totaled $406 million as of June 30, 2021
Gossamer Bio
Gossamer Bio
Forward Guidance
The Company expects the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023.